Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imagion Biosystems Ltd. ( (AU:IBX) ) has provided an update.
Imagion Biosystems has notified the ASX of the issue of 330,000 unquoted convertible notes and more than 10.6 million unquoted options, both dated 23 April 2026. The options, which expire in April 2029 with an exercise price of $0.0297, and the convertible notes form part of previously flagged financing arrangements and are not intended to be quoted, indicating continued use of structured capital instruments to support the company’s funding needs.
The issuance of these unquoted securities underscores Imagion Biosystems’ reliance on convertible debt and option-based incentives to raise capital and align stakeholders with long-term value creation. While the instruments do not immediately affect the quoted share capital, they introduce potential future dilution and highlight the company’s ongoing efforts to secure funding for its operations and development programs.
More about Imagion Biosystems Ltd.
Imagion Biosystems Ltd. is a biotechnology company listed on the ASX under the code IBX. The company focuses on developing medical technologies and related biosystem solutions, positioning itself within the life sciences and healthcare innovation sector.
Average Trading Volume: 1,744,631
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.3M
See more insights into IBX stock on TipRanks’ Stock Analysis page.